107 related articles for article (PubMed ID: 22354629)
1. Spiro[chromane-2,4'-piperidine]-based histone deacetylase inhibitors with improved in vivo activity.
Thaler F; Varasi M; Carenzi G; Colombo A; Abate A; Bigogno C; Boggio R; Carrara S; Cataudella T; Dal Zuffo R; Reali V; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
ChemMedChem; 2012 Apr; 7(4):709-21. PubMed ID: 22354629
[TBL] [Abstract][Full Text] [Related]
2. Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
Varasi M; Thaler F; Abate A; Bigogno C; Boggio R; Carenzi G; Cataudella T; Dal Zuffo R; Fulco MC; Rozio MG; Mai A; Dondio G; Minucci S; Mercurio C
J Med Chem; 2011 Apr; 54(8):3051-64. PubMed ID: 21417419
[TBL] [Abstract][Full Text] [Related]
3. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
[TBL] [Abstract][Full Text] [Related]
5. 4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.
Rossi C; Fincham CI; D'Andrea P; Porcelloni M; Ettorre A; Mauro S; Bigioni M; Binaschi M; Maggi CA; Nardelli F; Parlani M; Fattori D
Bioorg Med Chem Lett; 2011 Nov; 21(22):6767-9. PubMed ID: 21978679
[TBL] [Abstract][Full Text] [Related]
6. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
[TBL] [Abstract][Full Text] [Related]
7. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
Wang H; Yu N; Chen D; Lee KC; Lye PL; Chang JW; Deng W; Ng MC; Lu T; Khoo ML; Poulsen A; Sangthongpitag K; Wu X; Hu C; Goh KC; Wang X; Fang L; Goh KL; Khng HH; Goh SK; Yeo P; Liu X; Bonday Z; Wood JM; Dymock BW; Kantharaj E; Sun ET
J Med Chem; 2011 Jul; 54(13):4694-720. PubMed ID: 21634430
[TBL] [Abstract][Full Text] [Related]
8. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.
Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
Thaler F; Colombo A; Mai A; Amici R; Bigogno C; Boggio R; Cappa A; Carrara S; Cataudella T; Fusar F; Gianti E; di Ventimiglia SJ; Moroni M; Munari D; Pain G; Regalia N; Sartori L; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C; Varasi M
J Med Chem; 2010 Jan; 53(2):822-39. PubMed ID: 20017493
[TBL] [Abstract][Full Text] [Related]
11. Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
Kachhadia V; Rajagopal S; Ponpandian T; Vignesh R; Anandhan K; Prabhu D; Rajendran P; Nidhyanandan S; Roy AM; Ahamed FA; Surendran N; Rajagopal S; Narayanan S; Gopalan B
Eur J Med Chem; 2016 Jan; 108():274-286. PubMed ID: 26689485
[TBL] [Abstract][Full Text] [Related]
12. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W
Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304
[TBL] [Abstract][Full Text] [Related]
14. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
Hirata Y; Hirata M; Kawaratani Y; Shibano M; Taniguchi M; Yasuda M; Ohmomo Y; Nagaoka Y; Baba K; Uesato S
Bioorg Med Chem Lett; 2012 Mar; 22(5):1926-30. PubMed ID: 22321215
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity and pharmacokinetic properties of ARS-interacting multi-functional protein 1 (AIMP1/p43).
Han JM; Myung H; Kim S
Cancer Lett; 2010 Jan; 287(2):157-64. PubMed ID: 19573982
[TBL] [Abstract][Full Text] [Related]
17. 2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors.
Rajak H; Agarawal A; Parmar P; Thakur BS; Veerasamy R; Sharma PC; Kharya MD
Bioorg Med Chem Lett; 2011 Oct; 21(19):5735-8. PubMed ID: 21875796
[TBL] [Abstract][Full Text] [Related]
18. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
Moffat D; Patel S; Day F; Belfield A; Donald A; Rowlands M; Wibawa J; Brotherton D; Stimson L; Clark V; Owen J; Bawden L; Box G; Bone E; Mortenson P; Hardcastle A; van Meurs S; Eccles S; Raynaud F; Aherne W
J Med Chem; 2010 Dec; 53(24):8663-78. PubMed ID: 21080647
[TBL] [Abstract][Full Text] [Related]
20. Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability.
Benelkebir H; Marie S; Hayden AL; Lyle J; Loadman PM; Crabb SJ; Packham G; Ganesan A
Bioorg Med Chem; 2011 Jun; 19(12):3650-8. PubMed ID: 21420302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
